^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
FCARH143
i
Other names: FCARH143, autologous anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes, BCMA CAR-CD4+/CD8+ T-cells, BCMA-specific CAR-expressing CD4+/CD8+ T-lymphocytes
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS, Fred Hutchinson Cancer Center, National Cancer Institute
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
